Retatrutide vs Mounjaro: What the Research Actually Shows

Step 1: Understanding what each medicine actually is

Start with the basics, because the two drugs are genuinely different in how they work. Mounjaro contains tirzepatide, a molecule that activates two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Stimulating both pathways at once slows gastric emptying, reduces appetite signals in the brain and helps regulate blood sugar. This dual action is why tirzepatide is described as the only dual-agonist weight-loss medicine currently licensed in the UK. If you want a thorough breakdown of the mechanism, the tirzepatide guide on this site covers it in detail.

Retatrutide goes one step further. It targets three receptors rather than two, adding glucagon receptor activation to the GIP and GLP-1 pathways. In theory, the glucagon component can increase the rate at which the body burns stored energy, and if you are curious about what mixing retatrutide and tirzepatide would actually involve, that question is addressed in full on this site. The question of whether adding that third pathway produces clinically meaningful extra benefit, and at what cost in terms of tolerability, is precisely what the ongoing phase 3 trials are designed to answer.

So the phrase "mounjaro retatrutide" (often searched as though the two are interchangeable or related products) reflects understandable curiosity rather than clinical fact. They belong to the same broad family of gut-hormone medicines, but they are separate compounds at very different stages of development.

Step 2: Where the trial evidence sits right now

Phase 2 data for retatrutide, published in 2023, generated considerable discussion. In a trial of adults with obesity, the highest-dose group saw average weight reductions of around 17% over 24 weeks, with modelling suggesting further loss beyond that point. Those are striking early numbers, and they are why the question of retatrutide and tirzepatide keeps surfacing in searches.

But phase 2 trials are relatively small, shorter in duration, and designed primarily to explore dosing and safety signals rather than confirm efficacy at scale. Phase 3 trials involve thousands of participants, run for much longer, and are the evidence base regulators actually assess before considering a licence application. As of summer 2026, retatrutide's phase 3 programme is ongoing; no results have been published or submitted for regulatory review. The NICE technology appraisal for tirzepatide (TA1026) illustrates the kind of sustained, large-scale evidence that regulators and health technology bodies require before recommending a medicine.

By contrast, tirzepatide's SURMOUNT-1 trial ran for 72 weeks across thousands of adults and reported average weight reductions of around 20 to 21% at the 15 mg dose. That body of evidence took years to build, and it underpins the MHRA licence Mounjaro holds today. Retatrutide may eventually follow a similar path, but it has not yet.

Step 3: What this means if you are looking at treatment options now

The practical upshot is straightforward. Going from tirzepatide to retatrutide is not an option available anywhere in the world at the moment, because retatrutide cannot be prescribed. You cannot combine retatrutide with tirzepatide either, why mixing tirzepatide and retatrutide would not be appropriate is explained separately, but the short answer is that neither concurrent use nor self-sourcing an unlicensed compound is safe or legal in a UK context.

Some people wonder whether the two medicines could ever be used together or sequentially. The separate page on using retatrutide and Mounjaro together addresses that question directly. For now, if weight management treatment is what you are looking for, Mounjaro and Wegovy are the licensed options assessed through a UK prescriber. Our Mounjaro pricing page gives a straightforward account of what private treatment costs and what a legitimate prescription service includes, useful context if you are weighing up your options.

For anyone keeping an eye on the retatrutide pipeline, that is a reasonable thing to do. Clinical development moves, and if phase 3 results are strong and a licence application follows, that landscape will change. But medicine sitting in a trial database is not medicine you can put in your fridge door next to your Mounjaro pen, and a prescriber cannot advise you on a dose that does not legally exist yet. The question of whether retatrutide is the same as Mounjaro gets its own full answer on this site, if you want to go deeper on the science side by side. Our clinical team keeps across the evidence as it develops.

Step 4: The questions a prescriber would ask you today

If the underlying goal is to find the most effective licensed treatment for your situation, the relevant conversation is not about retatrutide, it is about whether Mounjaro or Wegovy suits you, what your BMI and health history look like, and what your prescriber thinks is appropriate after a full clinical assessment. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, dyslipidaemia, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

At nume (sorry, at our pharmacy) every consultation is read and assessed personally by a GPhC-registered Independent Prescriber on the same day it is submitted. No automated decisions. The weight-loss treatment overview sets out both licensed options side by side so you can arrive at that conversation already informed. The NHS medicines page for tirzepatide is also worth reading before you start, covering the expected side-effect profile and what to discuss with your prescriber. When you are ready to find out whether Mounjaro is clinically suitable for you, you can check your eligibility through a free consultation.